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OBJECTIVES We sought to study the effect of angiotensin-converting enzyme inhibition on exercise-
induced myocardial ischemia.
BACKGROUND Although angiotensin-converting enzyme inhibitors have been shown to reduce ischemic
events after myocardial infarction, few data are available regarding their direct anti-ischemic
effects in patients with coronary artery disease.
METHODS We studied 43 patients (average age 63 6 8 years) with exercise-induced myocardial ischemia
($0.1 mV ST depression, despite optimal beta blockade) and normal left ventricular function
(ejection fraction .0.50). In a double-blind, placebo-controlled parallel design, patients were
treated with angiotensin-converting enzyme inhibitor (enalapril 10 mg twice daily) or
placebo. Assessments were made after three weeks (short-term) and 12 weeks (long-term).
RESULTS At baseline, the groups were well matched for all clinical characteristics. After three weeks,
there was a slight but not significant increase in time to 0.1 mV ST depression in both groups
(p 5 NS); rate pressure product (RPP 5 heart rate 3 systolic blood pressure) was also
unaffected. After 12 weeks, however, time to 0.1 mV ST depression further increased in the
enalapril group (5.6 6 1.9 min) but was unchanged in the placebo group (4.4 6 1.3 min; p ,
0.05 between groups). In contrast, RPP was not affected. Concentrations of both atrial and
brain natriuretic peptides at peak exercise tended to be lower by enalapril, if compared to
placebo (p 5 NS).
CONCLUSIONS Angiotensin-converting enzyme inhibition may reduce exercise-induced myocardial ischemia
in patients with normal left ventricular function. Further studies are needed to elucidate the
mechanisms involved. (J Am Coll Cardiol 2001;37:470–4) © 2001 by the American College
of Cardiology
Angiotensin-converting enzyme inhibitors are used on a
large scale in the treatment of hypertension and heart
failure. Many patients with these conditions also have
coronary artery disease (CAD); current treatment consists of
beta blockade, long-acting nitrates and/or calcium antago-
nists (1). The objective of this treatment is to reduce
symptoms of angina pectoris and to prevent ischemic events.
Angiotensin-converting enzyme inhibitors have also been
shown to be of potential value in patients with CAD, with
reduced impaired left ventricular (LV) ejection fraction (2)
and after myocardial infarction (3), as their use reduces the
incidence of recurrent ischemic events in these patient
groups. How angiotensin-converting enzyme inhibitors ex-
ert this beneficial effect is largely unknown, although several
mechanisms, including a reduction in afterload and wall
stress, inhibition in neurohormonal activation, intracoro-
nary plaque stabilization, improvement of endothelial func-
tion and myocardial perfusion have all been suggested
(4–8). Nevertheless, data to support a direct anti-ischemic
effect of angiotensin-converting enzyme inhibitors in CAD
patients with normal blood pressure and normal LV func-
tion are scarce (9).
In the present study, we investigated the effect of
angiotensin-converting enzyme inhibition (with enalapril)
on exercise-induced myocardial ischemia in patients with
stable CAD, normal blood pressure and normal LV func-
tion who were symptomatic despite optimal treatment with
beta blockers. We examined this effect after short-term
treatment (three weeks) and after prolonged, long-term
treatment (12 weeks), because the majority of earlier studies
investigated only the short-term effects.
METHODS
The present study was a 12-week, randomized, parallel
double-blind comparison of enalapril (10 mg twice daily)
and placebo in 44 patients with ischemic heart disease.
Patients (male, aged 18–75 years) were normotensive and
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had a history of angina and signs of myocardial ischemia
during exercise ($0.1 mV ST-segment depression) despite
optimal beta blockade (resting heart rate ,65 beats/min at
rest). In patients with a history of myocardial infarction
(non-Q), left ventricular ejection fraction had to be deter-
mined and had to be .50%. Exclusion criteria included
unstable angina, symptoms and/or signs of congestive heart
failure, resting supine systolic blood pressure .200 or
,100 mm Hg, resting supine diastolic blood pressure
.100 mm Hg, a resting electrocardiographic pattern that
does not allow correct interpretation of ST-segment devia-
tion during the exercise stress test, history of hypersensitiv-
ity to angiotensin-converting enzyme inhibitors, renal in-
sufficiency (serum creatinine .130 mmol/L), electrolyte
abnormalities (K .5.2 mmol/L, Na , 130 mmol/L) and
myocardial infarction within the previous three months.
The only drugs allowed were beta-1-selective beta-blockers
(which were mandatory), long-acting nitrates and diuretics
(for hypertension) with dosages unchanged during the study
period; all other cardiovascular medication was excluded.
The protocol was approved by the Ethics Committee of
each participating center and all patients had to give their
written informed consent before entry into the study.
Analysis at screening included physical examination,
bicycle exercise test and laboratory investigation including
hematology and blood chemistry. The electrocardiogram
was monitored continuously to measure heart rate. ST-
segments were determined by hand, at a paper speed of 100
mm/s in five successive beats, 80 ms after the J point of the
QRS complex using a calibrated magnifying lens. This
monitoring was performed blinded to the study group. After
eligibility was determined, patients performed a second
symptom-limited exercise test one week later, with mea-
surements of neurohormones (atrial natriuretic peptide
[ANP] and brain natriuretic peptide [BNP]) at rest and at
maximal exercise. During this second test, exercise time had
to be within 15% of the first test; results of the second test
were taken as baseline. Patients were then randomized to
10 mg enalapril bid or placebo bid for 12 weeks. Patients
visited the outpatient clinic after three and 12 weeks and
assessments were repeated.
Exercise test and plasma neurohormones. Before the test,
at rest and during peak exercise, venous blood was taken
from an indwelling canula in the antecubital vein for
measurement of ANP and BNP. This canula had been
inserted .20 min before the exercise test and resting values
were taken in the supine position. The second sample was
taken during peak exercise. Plasma neurohormones were
measured at baseline (i.e., before the study) and after three
and 12 weeks. ANP and BNP were determined as previ-
ously described in detail (10). Normal values for ANP were
1 to 15 pmol/l and for BNP 1 to 10 pmol/L. All measure-
ments were performed in one batch at the core laboratory at
the Erasmus University Rotterdam.
Statistical analysis. Values are given as the mean value 6
SD. The primary end point, time to 0.1 mV ST-segment
depression at 12 weeks, was evaluated by analysis of covari-
ance (ANCOVA), by including the time to 0.1 mV ST-
segment depression as additional covariate. Baseline values
of all end points were analyzed by one-way ANOVA. If no
0.1 mV ST-segment depression was attained for the end
point time to 0.1 mV ST-segment depression, the total
exercise time was substituted. Comparison between the two
treatment groups for remaining continuous normally dis-
tributed variables was analyzed by one-way ANOVA and/or
skewed distributed variables by the Wilcoxon two-sample
test. Categorical variables were analyzed by the chi-square
test with continuity correction or Fisher exact test if
appropriate. A p-value ,0.05 was considered statistically
significant.
RESULTS
Forty-four patients (mean age 63 6 8 years) were included
(Table 1). All patients were treated with the beta blocker
metoprolol, except for one patient in the placebo and one
patient in the enalapril group who were treated with
atenolol. Twenty-three patients completed treatment with
enalapril; 20 patients with placebo. One patient in the
placebo group withdrew informed consent. The two groups
were well matched for all clinical parameters (Table 1).
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
CAD 5 coronary artery disease
LV 5 left ventricular
RPP 5 rate pressure product
Table 1. Patients’ Characteristics
Placebo Enalapril
Number 20 23
Age (years) 65 6 8 62 6 9
Height (cm) 173 6 7 178 6 6
Weight (kg) 79 6 12 85 6 9
Prev. MI 4 3
PTCA 2 5
CABG 3 6
AP (NYHA)
I 9 12
II 11 11
Blood pressure (mm Hg)
systolic 139 6 18 132 6 14
diastolic 78 6 9 77 6 9
Heart rate (beats/min) 62 6 6 62 6 5
Total cholesterol (mmol/l) 5.1 6 0.9 5.1 6 0.8
Long-acting nitrate 4 3
ANP rest (pmol/ml) 12.4 6 7.2 13.8 6 8.0
ANP exercise (pmol/ml) 23.5 6 18.2 30.5 6 17.5
BNP rest (pmol/l) 15.0 6 14.6 8.9 6 8.3
BNP exercise (pmol/l) 18.2 6 17.2 12.3 6 11.9
ANP 5 atrial natriuretic peptide; AP 5 angina pectoris; BNP 5 brain natriuretic
peptide; CABG 5 coronary artery bypass graft; MI 5 myocardial infarction;
NYHA 5 New York Heart Association; PTCA 5 percutaneous transluminal
coronary angioplasty.
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Results after three weeks (Table 2). Heart rate and blood
pressure were not affected after three weeks and there were
no differences between the groups. Time to 0.1 mV ST-
segment depression slightly increased in both groups (p 5
NS vs. baseline), but there was no difference between the
groups (Fig. 1).
Maximal ST depression, total exercise time and RPP
were also unaffected. Atrial natriuretic peptide and BNP at
rest were not affected by enalapril. During peak exercise,
however, the increase of both ANP and BNP tended to be
blunted by enalapril (p 5 0.08 for ANP and p 5 0.24 for
BNP vs. placebo) (Table 2).
Results after 12 weeks (Table 2). During prolonged treat-
ment, heart rate and blood pressure remained unaffected. In
contrast, time until 0.1 mV ST-segment depression further
increased in the enalapril group, whereas it returned to
baseline in the placebo group (p 5 0.036 between groups)
(Fig. 1).
Rate pressure product was again unaffected by study
medication. Total exercise and maximal ST-segment de-
pression were also unchanged. Plasma ANP and BNP at
rest were again unaffected while slight, but again nonsignif-
icant, decreases in peak values were observed.
DISCUSSION
The main finding of the present study is that enalapril
reduced exercise-induced myocardial ischemia in normoten-
Table 2. Exercise Test Parameters
Baseline
3 Weeks
Treatment
12 Weeks
Treatment
Max ST-segment depression (mV)
Enalapril 0.19 6 0.07 0.18 6 0.08 0.18 6 0.08
Placebo 0.21 6 0.10 0.19 6 0.10 0.19 6 0.10
Time to 0.1 mV ST depression
(min)
Enalapril 4.7 6 1.3 5.4 6 1.5 5.6 61.9*
Placebo 4.3 6 1.6 5.0 6 1.5 4.4 6 1.3
Total exercise time (min)
Enalapril 7.2 6 1.4 7.3 6 1.6 7.3 6 1.4
Placebo 6.6 6 2.0 6.7 6 2.1 6.5 6 2.1
Heart rate rest (beats/min)
Enalapril 61 6 9 60 6 8 63 6 11
Placebo 59 6 9 59 6 8 61 6 10
Heart rate peak (beats/min)
Enalapril 122 6 18 121 6 21 124 6 20
Placebo 123 6 13 123 6 15 125 6 16
Blood pressure rest syst/diast (mm
Hg)
Enalapril 141 6 23/81 6 10 133 6 25/78 6 10 134 6 22/77 6 11
Placebo 133 6 16/78 6 9 130 6 17/76 6 6 129 6 17/75 6 8
Blood pressure peak syst/diast
(mm Hg)
Enalapril 189 6 16/89 6 10 185 6 29/85 6 10 183 6 16/85 6 12
Placebo 174 6 14/86 6 9 175 6 15/85 6 8 175 6 23/84 6 7
RPP (mm Hgzmin1)
Enalapril 22162 6 4113 21735 6 4873 21853 6 3600
Placebo 20691 6 3139 20743 6 3591 21065 6 3989
Increase ANP (pmol/l)†
Enalapril 16.9 6 12.8 12.5 6 7.2 12.7 6 11.7
Placebo 11.2 6 17.6 11.9 6 11.3 9.8 6 11.9
Increase BNP (pmol/l)†
Enalapril 3.2 6 3.4 1.4 6 1.7 2.3 6 2.8
Placebo 2.8 6 5.1 3.8 6 3.6 2.8 6 4.3
*p , 0.05 between groups. †ANP/BNP during exercise minus ANP/BNP at rest.
ANP/BNP 5 atrial/brain natriuretic peptide; RPP 5 rate pressure product.
Figure 1. Time to 0.1 mV ST-segment depression at baseline after three
and 12 weeks treatment with study medication. Dotted line is placebo
group. After 12 weeks the difference between groups is significant (p 5
0.036).
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sive patients with normal LV function who had symptom-
atic angina despite optimal beta blockade. Enalapril in-
creased time to 0.1 mV ST-segment depression whereas
RPP was not affected. In addition, the increase of the
natriuretic peptides (ANP and BNP) during exercise tended
to be blunted during enalapril administration. Although this
effect did not reach statistical significance, this finding may
explain the observed decrease in exercise-induced ischemia.
The finding that most patients did not experience angina
during the exercise test may be explained by the fact that
patients stop before they experience angina pectoris.
Anti-ischemic effects of enalapril. Short-term studies
with angiotensin-converting enzyme inhibitors in normo-
tensive patients with stable, exercise-induced angina pecto-
ris and normal LV function have shown disappointing
results (6–8). In some of these studies, the observed absence
of a favorable effect was explained by a decrease in blood
pressure, leading to a reduction in coronary perfusion
pressure. These results are in contrast with the beneficial
effects described after long-term administration in patients
with CAD and LV dysfunction (3,11). In the latter studies,
the anti-ischemic properties of angiotensin-converting en-
zyme inhibition were not observed within 3–6 months of
treatment. This delayed onset of action may suggest that,
rather than direct hemodynamic effects on the myocardial
supply/demand ratio, other (indirect) effects, possibly on the
tissue/cellular level, are responsible for the long-term anti-
ischemic properties of angiotensin-converting enzyme in-
hibitors. By inhibition of angiotensin-converting enzymes,
these drugs not only prevent generation of the vasoconstric-
tor angiotensin II, but also stimulate prostanoid and nitric
oxide formation through local bradykinin accumulation,
thereby enhancing vasodilation (12–13). In addition, both
prostacyclin and nitric oxide prevent platelet aggregation by
increasing cyclic adenosine monophosphate in platelets.
These local effects may be attributable to the protective
properties of angiotensin-converting enzyme inhibitors in
CAD, which may lead to a better endothelial function (14).
Recently, the results of the Heart Outcomes Prevention
Evaluation (HOPE) study (15) showed that the
angiotensin-converting enzyme inhibitor ramipril reduced
the incidence of cardiovascular events and overt nephropa-
thy in people with diabetes. This cardiovascular benefit was
greater than that attributable to the decrease in blood
pressure, comparable with the lack of effect on RPP in the
present study.
Neurohormonal activation during myocardial ischemia.
Recently, we reported that during pacing-induced myocar-
dial ischemia the increase in ANP levels could be blunted by
angiotensin-converting enzyme inhibition with perindopri-
lat, while heart rate and blood pressure were unaffected (3).
Interestingly, this was accompanied with reduced myocar-
dial ischemia, as shown by lower plasma lactate levels and
ST depression. Recent studies have reported that ANP is a
good and early marker for ischemia-induced LV dysfunc-
tion (16). The effects of enalapril on ANP and BNP in the
present study, however, were not statistically significant.
This may be due to the small sample size (and the large
standard deviation), but possibly also to the use of beta
blockade as concomitant medication, as recent studies have
shown increased levels of natriuretic peptides after pro-
longed beta blocker treatment despite an improvement in
LV function (17,18).
Study limitations. Combination of antianginal medication
is only relevant in patients whose symptoms persist despite
optimal therapy with one drug (19). Hence, a prerequisite
for randomization was ischemia (ST-segment depression)
despite optimal beta blockade, defined in terms of heart rate
and ischemia during exercise. When considering patients
already on a single agent, the sample size to demonstrate
benefit of a second agent has to be large, and therefore this
study, because of its small sample size, cannot exclude a type
II statistical error (1).
Conclusions. In patients with stable CAD and normal LV
function who were symptomatic despite optimal beta block-
ade, angiotensin-converting enzyme inhibition by enalapril
reduced exercise-induced myocardial ischemia after pro-
longed treatment. Further (larger) studies will be needed to
examine underlying mechanisms.
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